Glucose-dependent Insulinotropic Polypeptide (human) (trifluoroacetate salt)

Name: Glucose-dependent Insulinotropic Polypeptide (human) (trifluoroacetate salt)
SKU: GC92134
Availability: InStock
Rating: 5 (30 reviews)

(Synonyms: Gastric Inhibitory Peptide; GIP) 目录号 : GC92134

Glucose-dependent Insulinotropic Polypeptide (human) (trifluoroacetate salt)是一种内源性42个氨基酸的肽促胰岛素素激素，在葡萄糖反应中诱导胰岛素分泌。

Glucose-dependent Insulinotropic Polypeptide (human) (trifluoroacetate salt) Chemical Structure

规格价格库存购买数量

1 mg

¥4,186.00

现货

电话：400-920-5774 Email: sales@glpbio.cn

Customer Reviews

Based on customer reviews.

Sample solution is provided at 25 µL, 10mM.

GlpBio产品文献引用

Nature
610.7931 (2022): 366-372

Nature
618, 1017–1023 (2023)

Cell
183.7 (2020): 1867-1883

Cell Research
31, 1291–1307 (2021)

Cell Research
33, 273–287 (2023)

Cell Research
33, 546–561 (2023)

Molecular Cancer
21.1 (2022): 1-17

Molecular Cancer
21.1 (2022): 1-18

Cancer Cell
39 (2021): 1-16

Cell Host Microbe
30.8 (2022): 1124-1138

Cell Host Microbe
31.5 (2023): 766-780

Cell Host Microbe
31.3 (2023): 418-43

Cell Metabolism
34.2 (2022): 240-255

Ann Rheum Dis
82(4): 533-545 (2023)

Cell Mol Immunol
20, 264–276 (2023)

Adv Funct Mater
33.35 (2023): 2214998

产品描述化学性质产品文档

Description

Glucose-dependent Insulinotropic Polypeptide (GIP) (human) is an endogenous 42-amino acid peptide incretin hormone that induces insulin secretion in response to glucose.¹ It belongs to the secretin/glucagon superfamily of peptides, which includes secretin, glucagon, glucagon-like peptide-1 (GLP-1, GLP-2), and pituitary adenylate cyclase-activating polypeptide (PACAP).² GIP is a GIP receptor agonist that binds to rat recombinant GIP receptors expressed in CHO-K1 cells (IC₅₀ = 3.2 nM) and increases cAMP accumulation (EC₅₀ = 377 pM).³ It stimulates insulin secretion from BRIN-BD11 rat pancreatic β-cells when used at a concentration of 10 nM.⁴ GIP (1 pmol/min per 100 g) decreases blood glucose level and increases plasma insulin level in rats following glucose challenge.³ It also decreases plasma glucose level and increases insulin level in ob/ob mice following glucose challenge when administered at a dose of 25 nmol/kg.⁵

References:
[1]. Baggio, L.L., and Drucker, D.J.Biology of incretins: GLP-1 and GIPGastroenterology132(6)2131-2157(2007).
[2]. Vaudry, D., Falluel-Morel, A., Bourgault, S., et al.Pituitary adenylate cyclase-activating polypeptide and its receptors: 20 years after the discoveryPharmacol. Rev.61(3)283-357(2009).
[3]. Hinke, S.A., Manhart, S., Pamir, N., et al.Identification of a bioactive domain in the amino-terminus of glucose-dependent insulinotropic polypeptide (GIP)Biochim. Biophys. Acta1547(1)143-155(2001).
[4]. Kerr, B.D., Flatt, A.J., Flatt, P.R., et al.Characterization and biological actions of N-terminal truncated forms of glucose-dependent insulinotropic polypeptideBiochem. Biophys. Res. Commun.404(3)870-876(2011).
[5]. O'Harte, F.P., Hunter, K., Gault, V.A., et al.Antagonistic effects of two novel GIP analogs, (Hyp3)GIP and (Hyp3)GIPLys16PAL, on the biological actions of GIP and longer-term effects in diabetic ob/ob miceAm. J. Physiol. Endocrinol. Metab.292(6)E1674-E1682(2007).

化学性质

Cas No.		SDF
别名	Gastric Inhibitory Peptide; GIP
化学名	L-tyrosyl-L-alanyl-L-α-glutamylglycyl-L-threonyl-L-phenylalanyl-L-isoleucyl-L-seryl-L-α-aspartyl-L-tyrosyl-L-seryl-L-isoleucyl-L-alanyl-L-methionyl-L-α-aspartyl-L-lysyl-L-isoleucyl-L-histidyl-L-glutaminyl-L-glutaminyl-L-α-aspartyl-L-phenylalanyl-L-valyl-L-asparaginyl-L-tryptophyl-L-leucyl-L-leucyl-L-alanyl-L-glutaminyl-L-lysylglycyl-L-lysyl-L-lysyl-L-asparaginyl-L-α-aspartyl-L-tryptophyl-L-lysyl-L-histidyl-L-asparaginyl-L-isoleucyl-L-threonyl-L-glutamine, trifluoroacetate salt
Canonical SMILES	[H]N[C@H](C(N[C@H](C(N[C@@H](CCC(O)=O)C(NCC(N[C@]([C@@H](C)O)([H])C(N[C@H](C(N[C@]([C@H](CC)C)([H])C(N[C@@H](CO)C(N[C@H](C(N[C@H](C(N[C@@H](CO)C(N[C@]([C@H](CC)C)([H])C(N[C@H](C(N[C@H](C(N[C@H](C(N[C@@H](CCCCN)C(N[C@]([C@H](CC)C)([H])C(N[C@H](C(N[C@@H](CCC(N)=O)C(N[C@@H](CCC(N)=O)C(N[C@H](C(N[C@H](C(N[C@@H](C(C)C)C(N[C@@H](CC(N)=O)C(N[C@H](C(N[C@@H](CC(C)C)C(N[C@@H](CC(C)C)C(N[C@H](C(N[C@@H](CCC(N)=O)C(N[C@@H](CCCCN)C(NCC(N[C@@H](CCCCN)C(N[C@@H](CCCCN)C(N[C@@H](CC(N)=O)C(N[C@H](C(N[C@H](C(N[C@@H](CCCCN)C(N[C@H](C(N[C@@H](CC(N)=O)C(N[C@]([C@H](CC)C)([H])C(N[C@]([C@@H](C)O)([H])C(N[C@@H](CCC(N)=O)C(O)=O)=O)=O)=O)=O)CC1=CN=CN1)=O)=O)CC2=CNC3=C2C=CC=C3)=O)CC(O)=O)=O)=O)=O)=O)=O)=O)=O)C)=O)=O)=O)CC4=CNC5=C4C=CC=C5)=O)=O)=O)CC6=CC=CC=C6)=O)CC(O)=O)=O)=O)=O)CC7=CN=CN7)=O)=O)=O)CC(O)=O)=O)CCSC)=O)C)=O)=O)=O)CC8=CC=C(O)C=C8)=O)CC(O)=O)=O)=O)=O)CC9=CC=CC=C9)=O)=O)=O)=O)C)=O)CC%10=CC=C(O)C=C%10.FC(F)(C(O)=O)F
分子式	C₂₂₆H₃₃₈N₆₀O₆₆S ? XCF₃COOH	分子量	4983.5
溶解度	Water: 1 mg/ml	储存条件	-20°C
General tips	请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。储备液的保存方式和期限：-80°C 储存时，请在 6 个月内使用，-20°C 储存时，请在 1 个月内使用。为了提高溶解度，请将管子加热至37℃，然后在超声波浴中震荡一段时间。
Shipping Condition	评估样品解决方案：配备蓝冰进行发货。所有其他可用尺寸：配备RT，或根据请求配备蓝冰。

溶解性数据

制备储备液
		1 mg	5 mg	10 mg
	1 mM	0.2007 mL	1.0033 mL	2.0066 mL
	5 mM	0.0401 mL	0.2007 mL	0.4013 mL
	10 mM	0.0201 mL	0.1003 mL	0.2007 mL

摩尔浓度计算器
稀释计算器
分子量计算器

计算

动物体内配方计算器 (澄清溶液)

第一步：请输入基本实验信息（考虑到实验过程中的损耗，建议多配一只动物的药量）

给药剂量

mg/kg

动物平均体重

每只动物给药体积

动物数量

只

第二步：请输入动物体内配方组成（配方适用于不溶于水的药物；不同批次药物配方比例不同，请联系GLPBIO为您提供正确的澄清溶液配方）

% DMSO+ % + % Tween 80+ % saline

计算重置

计算结果:

工作液浓度： mg/ml；

DMSO母液配制方法： mg 药物溶于 μL DMSO溶液（母液浓度 mg/mL，注：如该浓度超过该批次药物DMSO溶解度，请先联系GLPBIO）；

体内配方配制方法：取 μL DMSO母液，加入 μL PEG300，混匀澄清后加入μL Tween 80，混匀澄清后加入 μL saline，混匀澄清。

注意：1. 首先保证母液是澄清的；
2. 一定要按照顺序依次将溶剂加入，进行下一步操作之前必须保证上一步操作得到的是澄清的溶液，可采用涡旋、超声或水浴加热等物理方法助溶。
3. 以上所有助溶剂都可在 GlpBio 网站选购。

产品文档

Quality Control & SDS

View current batch:

Purity: >95.00%